echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > BMJ Open: Study on the treatment of chronic idio-constipation with different doses of Pakalopili

    BMJ Open: Study on the treatment of chronic idio-constipation with different doses of Pakalopili

    • Last Update: 2021-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Everyone has had a kind of "unspeakable secret" called constipation.
    and chronic idempo constipation (CIC) refers to persistent constipation that cannot be explained in terms of physiological structure or biochemistry.
    data show that the global adult CIC prevalence rate is about 14%, over 65 years of age, women may be a potential risk factor for the rise in prevalence.
    for gastrointestinal physicians and surgeons, there are daunting challenges to CIC management, and although laxatives and motivational agents are widely used in clinical practice, there is still insufficient evidence of long-term clinical efficacy.
    addition, weakened gastrointestinal peristaltic and damage to the intestinal nervous system (INS) significantly facilitated the occurrence of CIC.
    , it is recommended that reasonable treatment of CIC should focus on neurons in INS, which in turn improves CIC.
    recently, a study published in the journal BMJ Open showed that Prukapili was effective in treating CIC patients at doses of 1 mg, 2 mg or 4 mg.
    study, researchers searched databases such as PubMed, EMBASE, MEDLINE and Cochrane to select different doses of Paulopili's prospective trials.
    the first meta-analysis, weekly spontaneous detobation frequency (SBM) and sudden adverse events such as headache, arrhythmics, diarrhea, dizziness, nausea, and vomiting were combined.
    then sorted the probability of the best dose of Pucarobili through Bayesian analysis.
    results showed that 1mg (OR:2.40, 95% CI 1.32 to 4.37) and 2 mg (OR:2.37) were used in 14 high-quality randomized controlled trials (RCT) in 4328 patients. SBMs increased significantly after 55,95% CI 1.93 to 3.36) and 4 mg (OR:2.51, 95% CI 1.92 to 3.28) Prukapili.
    analysis showed a significant increase in SBMs using a 1 mg dose of Prucabili compared to 2mg and 4mg doses (OR: 3.31, 95% confidence interval 1.72 to 6.16, probability grade: 0.70).
    of different doses of PrukabiliSBMs However, in the area of TEAEs, 2 mg (risk ratio (RR): 1.20, 95% CI 1.09 to 1.33) and 4 mg (RR:1.1) 4,95% CI 1.07 to 1.22) Prukapili's TEAEs were significantly higher, while the 1 mg dose was not statistically significant (RR:1.17, 95% CI 0.94 to 1.44).
    TAAEs forest map with different doses of Prucabili, the use of 1 mg dose of Prukapili can effectively treat CIC, and the study has some limitations.
    is well known that CIC is a chronic intestinal dysfunction that requires long-term medication and therefore requires more extensive RCT and long-term efficacy assessments to balance the risk benefits of Pakalopili in CIC therapy.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.